Clinical Trial Update: The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of IBI-10090 for inflammation associated with cataract surgery has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Inflammation

Drugs mentioned

• IBI-10090 (IBI-10090)

Snippet

Sponsor: ICON Bioscience Inc | Conditions: Inflammation, Cataracts | Phase 3 | Status: COMPLETED | Results posted: 2018-04-23